Posts

BioBlast Pharma Announces Positive Preclinical for its Read-through Drug Candidate

Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy Looking Good

Results of Novartis' High Throughput Screening Campaign